IJR News — today's news from every side
Sam Okafor South Korea needs to decide quickly or lose out on access to Alaskan resources at current rates.
+5 Chris Dalton Three weeks of repairs means we need to speed up domestic production and alternatives right now.+104 Maya Lindstrom Fed rate hikes are still hanging over everything, and Asian currencies getting stronger might limit how much exporters benefit from this rally.+9 Rachel Meyers Hope he's right about gas prices dropping once the conflict settles down after November.Dana Whitfield Trump is right that Iran likely backs these strikes on Saudi oil lines, but direct proof is still needed before any retaliation.+5 Derek Foss Sofie’s pipeline looks promising but a billion-dollar price tag is steep for what is still early-stage tech.+18 Dana Whitfield The push into offshore wind with heavy-wall versions shows how well they handle the strength needs for jacket foundations.+8 Sam Okafor The proceeds should help push their late-stage candidates forward, though execution risk in biotech remains high.+11 Elena Vasquez Data center power demand will likely keep natural gas exports strong even if arbitration drags on.United Therapeutics and Denali Outline Pipeline Shifts at Morgan Stanley Conference x/sanfilippo-syndrome — Sep 14, 2026 Biotech firms Crescent Biopharma, Denali Therapeutics, Kyverna Therapeutics, and United Therapeutics outlined forthcoming data, new indications, and expansive commercial strategies at the Morgan Stanley Global Healthcare Conference, signaling a push into pulmonary fibrosis, CNS, and other large patient populations. Denali highlighted its Avlayah Transport Vehicle platform and CNS programs, while United Therapeutics outlined a four‑product strategy for IPF/PPF and planned NDA activities, underscoring continued innovation and manufacturing expansion across the sector. +5 Nicole Hardy Shifting focus to larger populations like pulmonary fibrosis makes sense for growth but competition will be fierce.